Tapi Fruit Processing Limited
NSE: TAPIFRUIT · Unclassified
Ask the data
Instant answers about Tapi Fruit Processing Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Revenue | 20.7 | 22.3 | 20.2 | 28.5 |
| EBITDA | 0.5 | 0.3 | -0.6 | 1.7 |
| Operating margin | 2.5% | 1.4% | -2.7% | 6.0% |
| Interest | 0.1 | 0.1 | 0.1 | 0.7 |
| Depreciation | 0.6 | 0.8 | 0.9 | 2.7 |
| Profit before tax | -0.2 | -0.2 | -1.4 | -1.7 |
| Tax | -0.0 | 0.0 | 0.1 | -0.0 |
| Net profit | -0.2 | -0.2 | -1.4 | -1.7 |
| EPS ₹ | -0.70 | -0.44 | -3.75 | 3.92 |
| Operating cash flow | -1.1 | -0.1 | 2.2 | -0.4 |
| Capex | 0.9 | 2.8 | 12.1 | 4.1 |
| Dividend paid | 0.0 | 0.0 | 0.0 | 0.0 |
| Total assets | — | — | 21.8 | 26.1 |
| Equity | — | — | 12.1 | 10.5 |
Half-yearly performance
last 8 half years · ₹ crore| H1 FY23* | H2 FY23 | H1 FY24 | H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.6 | 12.0 | 11.6 | 10.7 | 9.8 | 10.4 | 12.4 | 16.2 |
| Operating profit | 0.0 | 0.5 | 0.3 | 0.0 | -0.3 | -0.2 | 0.6 | 1.1 |
| Operating margin | 0.0% | 4.3% | 2.3% | 0.4% | -3.3% | -2.2% | 4.8% | 7.0% |
| Other income | 0.0 | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 | 0.0 | 0.0 |
| Interest | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | 0.4 |
| Depreciation | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 1.3 | 1.4 |
| Profit before tax | -0.4 | 0.2 | 0.0 | -0.2 | -0.8 | -0.6 | -1.0 | -0.7 |
| Tax | 0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | -0.0 |
| Net profit | -0.5 | 0.3 | 0.0 | -0.2 | -0.8 | -0.7 | -1.0 | -0.7 |
| EPS ₹ | -1.31 | 0.61 | -0.01 | -0.44 | 1.81 | -1.92 | -2.32 | 1.60 |
| Revenue YoY | — | — | 34.1% | -11.0% | -15.3% | -3.1% | 26.1% | 55.5% |
| Profit YoY | — | — | — | -173.1% | — | — | — | — |
Returns & margins
trailing-twelve-month, per half year| H2 FY23 | H1 FY24 | H2 FY24 | H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -8.1% | -11.9% | -14.8% | -15.9% |
| ROCE | — | — | — | -6.8% | -6.7% | -6.7% | -4.6% |
| Net margin | -0.9% | 1.1% | -0.9% | -4.6% | -7.1% | -7.3% | -5.9% |
| EBITDA margin | 2.5% | 3.3% | 1.4% | -1.4% | -2.7% | 1.6% | 6.0% |
| Debt / equity | — | — | — | 0.07 | 0.56 | 0.64 | 1.07 |
| Interest coverage | -0.33 | 7.00 | -1.67 | -14.33 | -14.11 | -3.54 | -1.45 |
| Asset turnover | — | — | — | 1.32 | 0.93 | 0.89 | 1.09 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|
| Share capital | 4.2 | 4.3 | 4.3 | 4.3 |
| Other equity / reserves | 6.8 | 7.8 | 6.9 | 6.2 |
| Total equity | 11.8 | 12.1 | 11.2 | 10.5 |
| Borrowings | 0.9 | 6.8 | 7.2 | 11.3 |
| Current liabilities | 3.0 | 4.6 | 9.4 | 9.3 |
| Non-current liabilities | 0.8 | 5.2 | 4.9 | 6.2 |
| Total assets | 15.5 | 21.8 | 25.6 | 26.1 |
| Property, plant & equipment | 5.2 | 6.5 | 16.8 | 16.9 |
| Investments | 1.5 | 0.0 | 0.0 | 0.0 |
| Inventories | 2.5 | 2.1 | 4.0 | 3.2 |
| Receivables | 1.2 | 1.4 | 2.2 | 1.9 |
| Cash & equivalents | 0.4 | 0.1 | 0.1 | 0.1 |
Cash flow
annual · ₹ crore · line = free cash flow| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Cash from operations | -1.1 | -0.1 | 2.2 | -0.4 |
| Cash from investing | -1.4 | -2.5 | -11.5 | -4.0 |
| Cash from financing | 2.6 | 6.0 | 5.8 | 4.4 |
| Capex | 0.9 | 2.8 | 12.1 | 4.1 |
| Free cash flow | -2.0 | -2.9 | -9.9 | -4.5 |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Tapi Fruit Processing Limited | 18 | 41.80 | — | 1.71 | -15.9% |
StoxGud checklist: Bearish setup · 1/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Tapi Fruit Processing Limited?
Tapi Fruit Processing Limited (TAPIFRUIT) closed at ₹41.80 on NSE on 05 Nov 2026.
What is the market cap of Tapi Fruit Processing Limited?
₹18 crore at the latest close.
How fast is Tapi Fruit Processing Limited growing?
Tapi Fruit Processing Limited: revenue has compounded at 11.3% a year over three years. Latest-half-year revenue is up 55.5% year on year.
How profitable is Tapi Fruit Processing Limited?
On a trailing-twelve-month basis return on equity is -15.9%, return on capital employed -4.6%, operating margin 6.0%, net margin -5.9%.
How much debt does Tapi Fruit Processing Limited have?
Tapi Fruit Processing Limited is moderately geared: debt to equity is 1.07 with borrowings of ₹11 cr against cash of ₹0 cr (balance sheet of 2026-03-31). Operating profit covers interest -1.4 times.
Financials parsed from Tapi Fruit Processing Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY23, annual from FY23, balance sheet from Sep '24. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.